Biomarcadores en Espondiloartropatías.

Autores/as

  • Consuelo Romero-Sánchez Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana|Instituto UIBO-Universidad El Bosque
  • John Londoño Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana
  • Juliette De Avila Instituto UIBO-Universidad El Bosque
  • Rafael Valle-Oñate Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana

Resumen

Introduction: Study of biomarkers (defined as molecules that reflect a biologic or specific pathological process) in rheumatic disease including spondyloarthropathies (SpA), has emerged as an important and necessary area among basic and clinic investigation, can be considered to reflect a biologic or specific pathological process, it’s consequence or the response to an intervention, there are others that provide information about the disease pathogenesis. In SpA has not been possible to find other biomarkers, and to assess the activity, it is necessary to resort to clinical test, as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI), since erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have demonstrated to be poor biomarkers, indicating us that the search of those in SpA must continue.

Objective: To describe the state the art of research of biomarkers of activity aimed at measuring and understanding of the pathogenesis in spondyloarthropathies.

Results: The ESR and CRP have shown poor performance measurement of activity. New candidates have been reported as promising as metalloproteinase 3, neopeptido C2C collagen, C propeptide of type II collagen, agrecan 846, colony stimulating factor Macrophage, serum amyloid A protein, IL-6, soluble CD14 among others, allowing direct the search for these markers related to immune response.

Conclusions: The rapid progression of the treatments with anti-TNF-alpha demand to have available methods to demonstrate in a sure way the asses of the activity due to it’s high costs in our environment. Thus it is necessary to establish objective measurements that help to rationalize resources. Previous Studies have allowed to orient the search of this markers related to the immune response.

Biografía del autor/a

Consuelo Romero-Sánchez, Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana|Instituto UIBO-Universidad El Bosque

Grupo Espondiloartropatías. Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana, Bogotá Colombia

Instituto UIBO-Universidad El Bosque, Bogotá Colombia

Bcl-MSc Candidata a DSc

María Consuelo Romero Sánchez

Dirección: Transversal 3 No. 49 – 00, tercer piso, Servicio de Reumatología e inmunología, Hospital Militar Central, Bogotá, Colombia

Fax: 057-1-3486868 ext. 5050, FAX. 057-1-8034515

John Londoño, Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana

Grupo Espondiloartropatías. Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana, Bogotá Colombia

Juliette De Avila, Instituto UIBO-Universidad El Bosque

Bcl-Esp Aspirante a MSc

Instituto UIBO-Universidad El Bosque, Bogotá Colombia

Rafael Valle-Oñate, Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana

Grupo Espondiloartropatías. Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana, Bogotá Colombia

Publicado

2010-09-08

Cómo citar

Romero-Sánchez, C., Londoño, J., De Avila, J., & Valle-Oñate, R. (2010). Biomarcadores en Espondiloartropatías. Revista Médica De Chile, 138(9). Recuperado a partir de https://revistamedicadechile.cl/index.php/rmedica/article/view/232

Número

Sección

Artículos de revisión

Artículos más leídos del mismo autor/a